Company profile
Viridian Therapeutics, Inc.
Framing the future of autoimmune diseases
- Industry
- Biotechnology Research
- Employees
- 391
- Headquarters
- Waltham, Massachusetts
- Founded
- 2007
- LinkedIn followers
- 29,158
- Office locations
- 2
Viridian Therapeutics, Inc. company summary
Viridian Therapeutics, Inc. is a company in the Biotechnology Research industry, headquartered in Waltham, Massachusetts, founded in 2007. On LinkedIn the company has around 391 employees and 29,158 followers. The company lists 2 office locations.
What technology does Viridian Therapeutics, Inc. use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Viridian Therapeutics, Inc.
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Where is Viridian Therapeutics, Inc. located?
Viridian Therapeutics, Inc. lists 2 office locations.
Compare companies similar to Viridian Therapeutics, Inc.
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Viridian Therapeutics, Inc. viridiantherapeutics.com | Biotechnology Research | 391 | 2007 | Waltham, Massachusetts |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Viridian Therapeutics, Inc.
What does Viridian Therapeutics, Inc. do?
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
How many employees does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has around 391 employees on LinkedIn.
Where is Viridian Therapeutics, Inc. headquartered?
Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.
Where does Viridian Therapeutics, Inc. have offices?
Viridian Therapeutics, Inc. lists 2 office locations, including Waltham, Massachusetts, US; Boulder, Colorado, US.
When was Viridian Therapeutics, Inc. founded?
Viridian Therapeutics, Inc. was founded in 2007.
Build a lead list from companies like Viridian Therapeutics, Inc.
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.